LL-37
Also known as: Cathelicidin, hCAP-18 C-terminal peptide, CAMP peptide
The human antimicrobial peptide — broad-spectrum pathogen defense with immune signaling properties.
Molecular structure image coming soon
Research use only. Not FDA-approved for human therapeutic use. Use under qualified medical supervision.
Overview
LL-37 is the only member of the cathelicidin family of antimicrobial peptides expressed in humans. It is produced by neutrophils, macrophages, and epithelial cells in response to infection. It has broad-spectrum antimicrobial activity against bacteria, viruses, fungi, and parasites, while also modulating immune responses. Deficiency has been linked to increased susceptibility to infections and inflammatory conditions.
Mechanism of Action
LL-37 disrupts bacterial cell membranes through direct membrane interaction. It also acts as a chemokine, attracting immune cells to sites of infection, modulates TLR signaling, promotes wound healing via receptor tyrosine kinase activation, and suppresses excessive inflammatory responses via NF-κB pathway modulation.
Use Cases
- ✓Chronic bacterial/viral infections
- ✓Antimicrobial defense support
- ✓Wound healing (topical)
- ✓Gut dysbiosis and microbiome support
- ✓Lung conditions (COPD, cystic fibrosis)
- ✓Skin conditions (rosacea, psoriasis)
Research Summary
Extensive preclinical evidence supports LL-37 in antimicrobial, wound healing, and immunomodulatory applications. Clinical research is ongoing in cystic fibrosis, chronic wounds, and cutaneous conditions. Lower LL-37 levels are associated with increased infection susceptibility in several disease states.
Typical Dosing
Protocols vary: 100–500 mcg subcutaneous injection. Topical formulations also available for skin/wound applications.
Administration
Research Chemical
Research use only. Not FDA-approved for human therapeutic use. Use under qualified medical supervision.
